PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma

Feng Liu1,2, Xu-ping Xi1,2*, Hui Wang1,2*, Ya-qian Han1,2, Feng Xiao1, Ying Hu1, Qian He1, Lin Zhang1, Qin Xiao1,2, Lin Liu1, Le Luo1, Yun Li1, Yi Mo1 and Hong-zhi Ma1

Abstract

Background: The effect of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)-guided dose-painting intensity-modulated radiation therapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) is unclear. This study aimed to assess the efficacy and toxicity of such combination.

Methods: From 2012 to 2014, 213 patients with stage III-IVB NPC received chemoradiotherapy by PET/CT-guided DP-IMRT (group A, n = 101) or CT-based IMRT (group B, n = 112). In group A, subvolume GTVnx-PET (gross tumor volume of nasopharynx in PET images) was defined within GTVnx (gross tumor volume of nasopharynx) as the SUV50%max isocontour; the dose to GTVnx-PET was escalated to DT 75.2 Gy/32 and 77.55 Gy/33 Fx, respectively, for patients with T1-2 and T3-4 disease, respectively. In group B, PGTVnx was irradiated at DT 70.4–72.6 Gy/32–33 Fx in 2.2 Gy per fraction.

Results: Complete response rates were 99.0% (100/101) and 92.9% (104/112) in groups A and B, respectively (P = 0.037). Compared with CT-based IMRT, FDG-PET/CT guided DP-IMRT significantly improved 3-year local failure-free survival (LFFS, 98.8% vs. 91.3%; P = 0.032), locoregional failure-free survival (LRFFS, 97.2 vs. 91.2%; P = 0.049), distant metastasis-free survival (DMFS, 92.9% vs. 87.4%; P = 0.041), disease free survival (DFS, 87.9% vs. 82.4%; P = 0.049), and overall survival (OS, 91.8% vs. 82.6%; P = 0.049). No statistically significant differences in acute and late toxic effects were observed. Multivariate analysis showed that dose painting (PET/CT-guided DP-IMRT vs CT-based IMRT without DP) was a significant independent prognostic factor for LFFS and DFS.

Conclusion: FDG-PET/CT guided DP-IMRT plus chemotherapy is associated with a considerable survival benefit, without increasing toxicity in patients with locoregional advanced NPC. Further randomized trials are needed to fully assess the role of PET/CT-guided DP-IMRT.

Keywords: Nasopharyngeal carcinoma, FDG-PET/CT, Dose painting, Intensity-Modulated Radiation Therapy, Toxicity

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia [1, 2]; definitive radiotherapy (RT) remains the mainstay of treatment for non-disseminated NPC [1, 3]. Although concurrent chemoradiotherapy is widely used in patients with locally advanced NPC, treatment results remain disappointing. The rate of local residual NPC is about 10%, while that of locally recurrent disease ranges from 16.8 to 23%, depending on initial tumor status [4, 5]. Since local control is directly related to mortality in NPC, there is a strong need to identify methods that further improve treatment outcome in NPC. Escalating the radiotherapy dose could improve local control, which is directly related to radiotherapy dose [6]. Various methods have been used to increase radiotherapy dose, including intra-cavitary brachytherapy [7, 8], stereotactic radiotherapy [4], and functional image-guided dose-escalation [9]. However, dose escalation in NPC may increase therapy-related complications because of high doses of irradiation to normal tissues [10]. The main challenge for such treatment is therefore to identify the appropriate tumor volume to be prescribed high radiation dose. In NPC, potential advantages of \(^{18}\)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) are increasingly recognized. PET provides biologic information regarding the tumor, complementing anatomic imaging. \(^{18}\)F-FDG-PET/CT possibly promotes accurate delineation and treatment of the tumor and extensions, while reducing the dose received by surrounding normal tissues [11]. We hypothesized that use of PET/CT-guided dose painting (DP) by numbers can determine the appropriate tumor volume to receive high-dose radiotherapy and improve dose-escalation radiotherapy for NPC; this in turn can improve therapeutic efficacy while reducing toxicity. There are limited studies assessing PET/CT-guided dose-escalation chemoradiotherapy in locoregionally advanced NPC, with very small sample size [9]. In addition, no clinical trials have directly compared PET/CT-guided dose-painting intensity modulated radiation therapy (DP-IMRT) to CT-based IMRT in locoregionally advanced NPC. Here, we retrospectively compared preliminary efficacy and toxicity profile of PET/CT-guided DP-IMRT versus CT-based IMRT in locoregionally advanced NPC patients.

Methods
Eligibility criteria
Between January 2012 and July 2014, 213 patients with locoregional advanced NPC were included in this study. Eligible patients were aged 18–70 years with non-metastatic, histologically proven WHO types II-III, stage III-IVB nasopharyngeal carcinoma (7th American Joint Committee on Cancer, AJCC). All participants had Karnofsky scores of at least 70, and adequate bone marrow (leukocyte count ≥4.0 × 10^9/L, absolute neutrophil count ≥1.5 × 10^9/L, platelets ≥100 × 10^9/L), liver, and renal functions. Patients were required to provide written informed consent before treatment. Exclusion criteria were: previous radiotherapy, another malignancy, pregnancy or lactation, active infection or unstable cardiac disease needing treatment. All patients were recruited from Hunan Cancer Hospital at The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University.

Radiotherapy
All patients underwent a pretreatment CT simulation scan with contrast injection on a spiral CT scanner in the treatment position and immobilization. In patients who received induction chemotherapy, CT simulation and MRI after induction chemotherapy were required. In patients not receiving induction chemotherapy, pretreatment CT simulation images were used for target volume delineation; in individuals who received induction chemotherapy, target volumes were delineated in CT simulation images after induction chemotherapy. Scanning scope was from the top of the head to the manubriosternal joint, with 2.5-mm increments. For patients of the PET/CT guided DP-IMRT group (group A), PET/CT scan was performed within 3 days of pretreatment CT simulation scan in the same position and immobilization. The FDG-PET scan was performed 1 h post-injection of 190–240 MBq of FDG. Data were acquired for 3 min per bed position. Patients were well hydrated, fasted for 6 h and glucose levels were below 10 mmol/L. The images were reconstructed to 2 × 2 × 2 mm^3 voxels using attenuation correction. The FDG-PET images were converted to SUV maps.

In group B, gross tumor volume (GTV) based on CT simulation images was delineated without using the FDG-PET images for dose painting; the corresponding target volumes were derived to achieve an IMRT plan [12–14]. Hard copies of MRI scans, PET/CT images, nasopharyngeal endoscopic examination findings, and pathology reports were available to both groups of patients for consideration in defining the target volumes. The pre-chemotherapy volume of the primary lesion was used for GTVnx (GTV of nasopharynx) delineation. Preinduction-chemotherapy volumes of involved lymph with extracapsular extension visualized on CT, MRI or PET-CT, and post-induction-chemotherapy volume of involved but encapsulated neck lymph nodes were used for GTVnd (GTV of the lymph node) delineation [14]. In group B, IMRT was delivered using linear accelerators with a nominal energy of 6 MV, and prescribed as follows: GTV of nasopharynx (GTVnx) was expanded outward by 5 mm (including the entire mucous membrane...
of the nasopharynx and 5 mm below it) [14], defined as PGTVnx, and irradiated at a dose of DT70.4 Gy/32 and DT72.6 Gy/33 Fx in patients with T1-2 and T3-4 disease, respectively, in increments of 2.2 Gy. GTV of the lymph node (GTVnnd) was irradiated at a dose of 69.96–72.6 Gy/32 to 33 Fx, in 2.12 to 2.2 Gy per fraction. High-risk subclinical lesions (PTV1) were irradiated at a dose of DT60.06 to 64 Gy/32 to 33 Fx, in 1.82 to 2.0 Gy per fraction. Lower-risk subclinical disease (PTV2) was treated at a dose of DT52.0 to 56.0 Gy/26 to 28 Fx, 1.82 to 2.0 Gy per fraction. Treatment plans were designed and optimized using the Pinnacle inverse planning system. Radiation therapy was administered from Monday to Friday for 32–33 days. In group A, the PET/CT-guided DP-IMRT regimen was used. Target volumes were then delineated on PET/CT images fused with CT simulation images obtained by a group of experienced radiation oncologists, assisted by an experienced nuclear medicine physician. The criteria for defining suspicious disease on FDG-PET/CT relied on visual criteria. Abnormal FDG uptake was defined as an abnormal FDG increased uptake outside normal anatomic structures, higher uptake than background activity or uptake in the location of an anatomic structure, but with asymmetric or higher than expected intensity [11]. Using the simultaneous integrated boost (SIB) technique, a subvolume GTVnx-PET was defined within the GTVnx as the 50% isocontour of the maximum standardized uptake value (SUV50%max). Dose to GTVnx-PET was escalated to DT75.2 Gy/32 Fx in patients with T1-2 disease, and DT77.55 Gy/33 Fx in those with T3-4 disease, in 2.35 Gy per fraction. Other target volumes were delineated as in group B and the same dose was used as in group B. Dose constrains to critical structures were within tolerance according to the RTOG 0225 protocol, and efforts were made to meet these criteria as closely as possible. Median volume of GTVnx was 38.2 ml (range: 5.6–186.6 ml) in group A and 39.4 ml (range: 5.8–176.8 ml) in group B \((P = 0.42)\); median volume of GTVnx-PET was 13.8 ml (range: 1.2–32.6 ml).

**Chemotherapy**

The induction chemotherapy regimen included TP (docetaxel at 75 mg/m²/day or paclitaxel 135–175 mg/m²/ day on day 1, in combination with cisplatin at 25 mg/ m²/day on days 1–3), PF (cisplatin at 25 mg/m²/day and 5-fluorouracil at 500 mg/m²/day on days 1–3). Concurrent chemotherapy was prescribed as 75 mg/m² cisplatin alone every 3 weeks. All patients were scheduled to receive concurrent chemotherapy except for those declining the treatment or presenting severe adverse events. Adjuvant chemotherapy was administered in the same manner as induction chemotherapy. The course of chemotherapy ranged from 3 to 7 cycles.

**Patient assessment and follow-up**

Follow-up duration was measured from the first day of treatment to last follow-up date (April 1, 2016) or the date of death. Complete blood cell counts and biochemical profiles were assessed once a week during the treatment period. We graded chemotherapy-related toxic effects in accordance with Common Terminology Criteria for Adverse Events (version 3.0). We graded radiotherapy-related toxic effects in accordance with both the Acute and the Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group (RTOG) [1, 9]. Tumor response was evaluated by physical examination, nasopharyngoscopy, and MRI of the head and neck, at 3 months after RT completion. Tumor response was classified according to the WHO response criteria [12, 15]. Complete response (CR) was defined as the complete disappearance of all objective evidence of disease, confirmed by physical examination, direct nasopharyngoscopy, and MRI. After treatment completion, the patients were assessed every 3 months during the first 3 years, and every 6 months thereafter until death or study end. Recurrence was defined as tumor recurrence after the tumor was undetectable for at least 1 month. All local recurrences were diagnosed with fibreoptic endoscopy and biopsy, MRI scan, or both, of the nasopharynx and the skull base showing progressive bone erosion and soft tissue swelling. Regional recurrences were diagnosed by clinical examination of the neck and, in doubtful cases, by fine needle aspiration or an MRI scan of the neck. Distant metastases were diagnosed by clinical symptoms, physical examinations, and imaging methods that included chest radiography, bone scan, MRI, CT, and abdominal sonography.

**Statistical analysis**

The primary endpoint was disease free survival (DFS). Secondary endpoints were local failure-free survival (LFFS), regional failure-free survival (RFFS), locoregional failure-free survival (LRFFS), distant metastasis-free survival (DMFS), overall survival (OS), initial response rates after treatment, and toxic effects. LFFS was defined as the time from admission (initiation of treatment) to local failure of primary tumor area. RFFS was defined as the time from admission to failure of non-primary tumor within the treatment regions. Disease free survival was assessed from admission to the date of tumor recurrence, distant metastasis or death, whichever came first. OS was defined as time elapsed from admission to the date of death from any cause or last follow-up. For locoregional and distant failure-free survival analyses, latencies were recorded from admission to first locoregional and remote failure, respectively.

The initial response rates, toxic effects, and other categorical variables were compared by the \( \chi^2 \) test. Kaplan-Meier survival curves were used to assess time-to-event

endpoints, with the log-rank test used to compare the two groups. Multivariable analyses were performed using the Cox proportional hazards model to evaluate treatment interventions. Potentially important prognostic factors considered in the modeling process were patient age (≤45 vs >45 years), sex (male vs female), tumor stage (T1-2 vs T3-4), node stage (N0-1 vs N2-3), induction chemotherapy (yes vs no), concurrent chemotherapy (yes vs no), pretreatment Epstein-Barr virus deoxyribonucleic acid (EBV DNA) concentration (<4000 copies/ml vs ≥4000 copies/ml) and dose painting (PET/CT-guided DP-IMRT vs CT-based IMRT without DP). All statistical analyses were performed using Statistical Package for the Social Sciences version 18.0 (SPSS, Chicago, IL, USA). All statistical tests were two-sided, with \( P < 0.05 \) considered statistically significant.

**Results**

**Patient characteristics**

Between January 2012 and July 2014, 213 patients with locoregional advanced nasopharyngeal carcinoma were included in this study. One hundred and one patients received FDG-PET/CT-guided DP-IMRT, and 112 patients were administered CT-based IMRT. Median follow-up time for all patients was 36 months (range, 8.5–50 months), and 36 months for surviving patients (range, 15.5–50 months). Detailed patient characteristics are shown in Table 1. No significant differences were found between the two treatment groups in terms of baseline demographic and clinical characteristics.

**Response rates**

Complete response rates, evaluated 3 months after RT completion, were 99.0% (100/101) and 92.9% (104/112) in groups A and B, respectively (\( P = 0.037 \)). In group A, one patient had residual neck lymph nodes. Six group B patients had residual neck lymph nodes and two presented residual nasopharyngeal tumors. The two patients with residual nasopharyngeal tumors underwent salvage chemotherapy. Only three patients with residual neck lymph nodes were found in group B at 6 months after RT completion, and successfully underwent salvage neck dissection.

**Adverse events and compliance**

All patients in both treatment groups completed the prescribed RT dose. A total of 56 (26.3%) patients received induction chemotherapy. Among them, four patients did not receive concurrent chemotherapy. Concurrent chemotherapy was administered to 209 (98.1%) patients. Adjuvant chemotherapy was provided to 20 (9.4%) patients with tumor presence at the completion of radiotherapy (Table 1). Reasons for withdrawal from chemotherapy included severe mucositis, prolonged severe neutropenia and patient’s refusal. The main grade 3–4 acute adverse events were mucositis and hematologic reactions; grade 3–4 late adverse events included skin fibrosis and ototoxicity (Table 2). No grade 5 toxicity (death) occurred during the treatment. There were no statistically significant differences between the two study groups in cumulative incidence of 3–4 acute and late toxic effects during follow-up (Table 2). One group B patient developed grade 1 temporal lobe necrosis not affecting job performance or daily life activities.

**Patterns of treatment failure**

Twelve (11.9%) and 24 (21.4%) patients in groups A and B, respectively, developed tumor recurrence (Table 3). Among the patients who developed distant organ metastases, 26, 11, and 13 had bone, liver, and lung metastases, respectively. Seventeen patients had metastases in more than one organ. Salvage treatments, including chemotherapy, re-irradiation, and surgery, were administered to patients after documented relapse, in accordance with standard practice.

**Survival**

Twenty-nine deaths (10 in group A and 19 in group B) were reported. In group A, causes of death were distant metastases (6 patients), local recurrence and severe malnutrition (2 patients), non-radiation induced cerebral hemorrhage (2 patients). In group B, death was from distant metastases (12 patients), local recurrence and severe malnutrition (5 patients), non-radiation induced cerebral hemorrhage (1 patient) and traumatic brain injury (1 patient). The rates for 3-year LFFS, LRFFS, DMFS, DFS and OS in groups A and B were 98.8% vs. 91.3% (\( P = 0.032 \)), 97.2 vs. 91.2% (\( P = 0.049 \)), 92.9% vs. 87.4% (\( P = 0.041 \)), 87.9% vs. 82.4% (\( P = 0.02 \)) and 91.8% vs. 82.6% (\( P = 0.049 \)), respectively (Fig. 1). No statistically significant differences were observed in RFFS between groups A and B (97.2% vs 92.4%, \( P = 0.217 \)) (Fig. 1). Dose escalation by FDG-PET/CT guided dose-painting IMRT resulted in 7.5%, 6.0%, 5.5%, 5.5% and 9.2% increases in 3-year LFFS, LRFFS, DMFS, DFS and OS rates, respectively, in group A.

**Prognostic factors**

The univariate analysis revealed that the factors influencing the 3-year OS were dose painting (PET/CT-guided DP-IMRT vs CT-based IMRT without DP; \( P = 0.049 \)) and EBV DNA concentration (\( P = 0.001 \)), respectively. The factors influencing DFS were dose painting (\( P = 0.020 \)) and EBV DNA concentration (\( P = 0.001 \)), respectively. The factors influencing DMFS were dose painting (\( P = 0.041 \)), EBV DNA concentration (\( P = 0.002 \)), and sex (\( P = 0.026 \)) respectively. The factors influencing LFFS were dose painting (\( P = 0.023 \)) and EBV DNA concentration (\( P = 0.002 \)), respectively. The factors influencing LRFFS were dose painting (\( P = 0.049 \)) and EBV DNA concentration (\( P = 0.008 \)), respectively.
respectively. The EBV DNA concentration ($P = 0.036$) was a significant prognostic factor to predict 3-RFFS. However, age, T stage, N stage, induction chemotherapy and concurrent chemotherapy were not the factors for significantly influencing the OS, DFS, LFFS, RFFS or LRFFS. Multivariate analyses showed that dose painting was a significant independent prognostic factor for 3-year LFFS and DFS ($P = 0.039$ and $P = 0.036$, respectively); EBV DNA concentration was a significant independent prognostic factor for 3-year LFFS, DFS, DMFS and OS ($P = 0.022$, $P < 0.001$, $P = 0.003$ and $P = 0.003$, respectively), and dose painting was of marginal significance in predicting DMFS and OS ($P = 0.075$, $P = 0.052$, respectively). The results of multivariate analysis are summarized in Table 4.

### Table 1 Characteristics of patients with locoregional advanced NPC assessed in this study

| Characteristic            | PET/CT-guided DP-IMRT | CT-based IMRT | $p$ value* |
|---------------------------|------------------------|--------------|------------|
|                           | No. of patients (%)    | No. of patients (%) |          |
| Total                     | 101                    | 112          |            |
| Age, y                    |                        |              |            |
| Median                    | 46                     | 47           |            |
| Range                     | 22–70                  | 18–67        |            |
| Sex                       |                        |              |            |
| Male                      | 66 (65.3)              | 78 (69.6)    | 0.464      |
| Female                    | 35 (34.7)              | 33 (29.5)    |            |
| Pathology                 |                        |              |            |
| WHO type 2                | 30 (29.7)              | 37 (33.0)    | 0.659      |
| WHO type 3                | 71 (70.3)              | 75 (67.0)    |            |
| T stage                   |                        |              |            |
| T1                        | 10 (9.9)               | 13 (11.6)    | 0.955      |
| T2                        | 27 (26.7)              | 30 (26.8)    |            |
| T3                        | 30 (29.7)              | 30 (26.8)    |            |
| T4                        | 34 (33.7)              | 39 (34.8)    |            |
| N stage                   |                        |              |            |
| N0                        | 3 (3)                  | 3 (2.7)      | 0.654      |
| N1                        | 10 (9.9)               | 6 (5.4)      |            |
| N2                        | 67 (66.3)              | 79 (70.5)    |            |
| N3                        | 21 (20.8)              | 24 (21.4)    |            |
| AJCC stage group          |                        |              |            |
| III                       | 49 (48.5)              | 59 (52.7)    | 0.790      |
| IVA                       | 32 (31.7)              | 31 (30.7)    |            |
| IVB                       | 20 (19.8)              | 22 (19.8)    |            |
| EBV DNA                   |                        |              |            |
| $\geq 4000$ copies/ml     | 49 (48.5)              | 46 (40.7)    | 0.334      |
| $< 4000$ copies/ml        | 52 (51.5)              | 66 (59.3)    |            |
| Concurrent chemotherapy   |                        |              |            |
| Yes                       | 99 (98.0)              | 110 (98.2)   | 0.649      |
| No                        | 2 (2)                  | 2 (1.8)      |            |
| Induction chemotherapy    |                        |              |            |
| Yes                       | 26 (25.7)              | 30 (26.8)    | 0.875      |
| No                        | 75 (74.3)              | 82 (73.2)    |            |
| Adjuvant chemotherapy     |                        |              |            |
| Yes                       | 8 (7.9)                | 12 (10.7)    | 0.490      |
| No                        | 93 (92.1)              | 98 (89.3)    |            |

*p values were calculated by the $\chi^2$ test
Discussion
For locoregional advanced NPC, chemoradiation is the standard of care [1, 12, 16, 17]. Despite recent progress in radiotherapy and chemotherapy, local residual and recurrent disease remains challenging. Dose-escalation in a homogeneous fashion to GTV is, however, restricted by increased risk of toxicity to normal structures (i.e. spinal cord, brain stem and optic nerve). A promising approach to increase local control (and consequently overall survival) is to take advantage of intra-tumor heterogeneity. Local failure in NPC appears most frequently at the primary tumor site and within the irradiated target volume with highest FDG uptake. These findings suggest that boosting these high uptake regions might improve local control. One strategy to accomplish dose-escalation while minimizing toxicity is dose painting, which is defined as locally boosting the tumor to increase locoregional control based on functional imaging (i.e. PET). Dose painting enables mapping of dose prescription to non-uniform distribution of metabolic, biochemical, and molecular abnormalities within the tumor [18–20]. FDG-PET/CT is increasingly used in dose painting for NPC. Integration of FDG-PET in IMRT planning has been described as beneficial for treatment individualization and dose escalation [21]. Furthermore, FDG-PET directed dose distribution could lead to better sparing of organs at risk, such as parotid glands [22, 23]. Various PET-based threshold methods have been proposed for target volume delineation, including SUV2.5, SUV50%max, and signal/background ratio (SBR) [9, 22, 24, 25]. In this study, SUV50%max target was selected as the clinical standard for dose escalation. This choice was motivated by the observation that in ongoing clinical trials, dose painting by contours is performed on SUV50%max isocontour [22, 26]. In general, GTV in IMRT is defined by CT imaging (or fusion of CT with MRI). This study aimed to compare PET/CT-guided DP-IMRT and CT-based IMRT. PET/CT-guided DP-IMRT is an effective technique for dose-escalation, and significantly increases the biologically effective dose (BED) delivered. Based on a linear-quadratic equation with an alpha/beta ratio of 10 for tumor response, the

| PET/CT-guided DP-IMRT | CT-based IMRT | p value* |
|-----------------------|---------------|----------|
| Acute adverse events  |               |          |
| Anemia                | 1 (1.0)       | 2 (1.8)  | 0.54     |
| Neutropenia           | 8 (7.9)       | 11 (9.8) | 0.63     |
| Leukopenia            | 15 (14.9)     | 18 (16.1)| 0.85     |
| Thrombocytopenia      | 1 (1.0)       | 1 (0.9)  | 0.73     |
| Liver dysfunction     | 0             | 0        |          |
| Nephrotoxicity        | 0             | 0        |          |
| Nausea                | 14 (13.9)     | 17 (15.2)| 0.85     |
| Vomiting              | 10 (9.9)      | 13 (11.6)| 0.83     |
| Mucositis             | 31 (30.7)     | 34 (32.1)| 0.77     |
| Dermatitis            | 9 (8.9)       | 12 (10.7)| 0.82     |
| Dysphagia or odynophobia | 3 (2.9) | 5 (4.5)  | 0.72     |
| Dry mouth             | 3 (2.9)       | 6 (5.3)  | 0.50     |
| Ototoxicity           | 0             | 1 (0.9)  | 0.53     |
| Late adverse events   |               |          |
| Skin fibrosis         | 0             | 1 (0.9)  | 0.53     |
| Dry mouth             | 0             | 0        |          |
| Ototoxicity           | 0             | 1 (0.9)  | 0.53     |
| Trismus               | 0             | 0        |          |
| Nasopharyngeal ulceration | 0        | 0        |          |

*p values were calculated by the χ² test

Table 3 Incidence and site of recurrence

| Site                      | PET/CT-guided DP-IMRT | CT-based IMRT |
|---------------------------|------------------------|---------------|
| Locoregional only         | 3 (3.0)                | 6 (5.3)       |
| Distant only              | 8 (7.9)                | 13 (10.6)     |
| Locoregional and distant  | 1 (1.0)                | 5 (4.5)       |
BED was significantly increased to 92.9–95.8 Gy to GTVnx-PET in group A compared to 85.9–88.6 Gy to GTVnx in group B.

Complete response rates after chemoradiotherapy for locoregional advanced NPC vary from 82.8 to 99% [1, 27, 28]. In this study, CR rate was significantly higher in the PET/CT-guided DP-IMRT group than in patients administered CT-based IMRT (99.0% vs 92.9%, \( P = 0.037 \)), suggesting that the risk for local residual tumor was significantly decreased by dose escalation using the DP-IMRT technique. Our findings using a PET/CT-guided DP-IMRT regimen demonstrated that LFFS, DMFS and OS compared favorably to other reports using CT-based IMRT and chemotherapy for NPC patients [14, 28, 29]. Liu et al. [28] reported that 185 patients with stage III to IVb NPC were treated by CT-based IMRT and chemotherapy. For patients with detectable EBV DNA levels and patients with undetectable EBV DNA levels, 3-year LRFS, PFS, and DMFS rates were 82.7% and 93.5%, 71.1% and 85.9%, 86.6% and 90.6%, respectively. He et al. [29] treated 358 patients with locally-advanced NPC using CT-based IMRT with chemotherapy, the 3-year OS, LRFS, DMFS, and DFS were 88.8 vs. 78.4%, 96.5 vs. 91.1%, 87.8 vs. 79.3%, and 84.1 vs. 69.6% for the patients with the distance between the primary tumor and brainstem (Dbs) > 4.7 vs. \( \leq 4.7 \) mm, respectively. Only few studies using DP-IMRT or PET/CT-guided IMRT for NPC have been reported, all with very small sample size. Bakst et al. [10] evaluated 25 NPC patients (stage II-IVB) treated with DP-IMRT
and chemotherapy; the prescribed radiation dose was 70.2 Gy using 2.34 Gy fractions to GTV. The 3-year local control rate was 91%, for 91% DMFS and 89% OS. Compared to Bakst et al.’s results, the present study showed better LFFS, DMFS and OS in the PET/CT-guided DP-IMRT group. The reason might be the higher total dose and fractionated dose to GTVnx-PET in the present study than the dose to GTV in Bakst et al.’s study. Wang et al. [9] compared conventional RT (group A), CT-based IMRT (group B) and PET/CT-guided IMRT (group C) in 67 locally advanced NPC patients. For group C, areas with an SUV threshold of 2.5 (SUV2.5) on PET/CT images were defined as GTV, which received 77Gy in group C, in 2.4 Gy per fraction. PET/CT-guided IMRT treated patients showed significantly higher 3-year local progression-free survival (LPFS) and DFS (LPFS, 100% vs 95.8%, \(P < 0.05\); DFS, 95.2% vs 79.2%, \(P < 0.05\)) compared with the conventional RT group. Meanwhile, there was no statistically significant difference in survival rates between PET/CT-guided IMRT and CT-based IMRT groups. The present study showed that 3-year LFFS, LRFFS, DMFS, DFS and OS were significantly higher in PET/CT-guided DP-IMRT group compared with CT-based IMRT group values. A relatively large sample size was assessed here, with the PET/CT-guided dose-painting technique performed on SUV50%max isocontour, which had smaller volumes than in the SUV2.5 based segmentation method [30]. Compared with threshold of SUV2.5, dose escalation on SUV50%max isocontour (GTVnx-PET) in this study could potentially improve therapeutic efficacy while reducing the dose to surrounding healthy tissues. Distant metastasis was the major cause of death in patients after treatment; our results suggested that the risk of distant metastasis was significantly decreased with increased local control rates, consequently increasing overall survival.

As shown above, the PET/CT-guided DP-IMRT regimen did not result in increased acute toxicities, indicating that treatment was well tolerated. Furthermore, no patients required significant treatment interruptions during radiation. Late toxicities included skin fibrosis, ototoxicity, and asymptomatic temporal lobe necrosis, and had similar rates between the two groups. Compared to studies by Lin et al. [14] and Lee et al. [12] assessing CT-based IMRT and chemotherapy in NPC patients, the PET/CT-guided DP-IMRT regimen in this study showed no increase in acute and late toxicities. In addition, no in-field cranial nerve injury and massive nasopharyngeal hemorrhage were observed in either group in this study. Wang et al. [9] revealed the most common acute toxicity of PET/CT-guided IMRT to be acute mucositis, while no grade 4 acute toxicities were noted. Late toxicities were subcutaneous fibrosis, xerostomia, and hearing loss. No significant differences were observed in acute and late toxicities between the PET/CT-guided IMRT and CT-based IMRT groups. In this study, limitation of the mean dose to each cochlea was ≤45 Gy, to reduce the incidence of significant hearing loss [13, 31]. One (0.9%) patient with significant tumor extension to the ipsilateral skull base in the CT-based IMRT group developed grade 3 hearing loss. To ensure the radical radiation dose to PTV for tumor control,

### Table 4 Multivariable analysis of prognostic factors in locoregional advanced NPC

| Endpoint                      | HR (95% CI) | p value*  |
|-------------------------------|-------------|-----------|
| Local failure-free survival   |             |           |
| Sex                           | 0.608 (0.201–1.844) | 0.380     |
| Age                           | 0.955 (0.311–2.937) | 0.936     |
| T stage                       | 0.733 (0.197–2.733) | 0.644     |
| N stage                       | 0.938 (0.114–7.738) | 0.953     |
| Induction chemotherapy        | 1.321 (0.148–11.759) | 0.803     |
| Concurrent chemotherapy       | >100 (0.000–) | 0.988     |
| EBV DNA level                 | 0.089 (0.011–0.701) | 0.022     |
| Dose painting                 | 0.239 (0.061–0.932) | 0.039     |
| Disease free survival         |             |           |
| Sex                           | 1.504 (0.704–3.214) | 0.292     |
| Age                           | 1.261 (0.659–2.410) | 0.484     |
| T stage                       | 1.504 (0.704–3.214) | 0.513     |
| N stage                       | 1.261 (0.629–2.531) | 0.649     |
| Induction chemotherapy        | 1.650 (0.524–5.197) | 0.392     |
| Concurrent chemotherapy       | 0.659 (0.135–3.222) | 0.606     |
| EBV DNA level                 | 0.170 (0.069–1.417) | <0.001    |
| Dose painting                 | 0.462 (0.225–0.951) | 0.036     |
| Distant metastasis-free survival |          |           |
| Sex                           | 3.334 (0.991–11.222) | 0.052     |
| Age                           | 1.697 (0.781–3.688) | 0.182     |
| T stage                       | 1.103 (0.471–2.581) | 0.821     |
| N stage                       | 0.688 (0.141–3.354) | 0.664     |
| Induction chemotherapy        | 1.426 (0.298–6.829) | 0.657     |
| Concurrent chemotherapy       | 0.640 (0.072–5.659) | 0.688     |
| EBV DNA level                 | 0.218 (0.079–0.601) | 0.003     |
| Dose painting                 | 0.453 (0.190–1.082) | 0.075     |
| Overall survival              |             |           |
| Sex                           | 1.456 (0.596–3.553) | 0.049     |
| Age                           | 1.166 (0.543–2.504) | 0.649     |
| T stage                       | 1.264 (0.558–2.860) | 0.575     |
| N stage                       | 0.264 (0.032–2.203) | 0.218     |
| Induction chemotherapy        | 2.664 (0.794–8.937) | 0.113     |
| Concurrent chemotherapy       | 0.328 (0.064–1.674) | 0.180     |
| EBV DNA level                 | 0.223 (0.082–0.607) | 0.003     |
| Dose painting                 | 0.425 (0.179–1.009) | 0.052     |

*p values calculated with the adjusted Cox proportional-hazards model
the ipsilateral cochlea inevitably received a mean dose of 52 Gy. Bakst et al. [10] reported a patient with clinically significant (grade 3) hearing loss. In all, 12% of patients developed temporal lobe necrosis, with one requiring surgical resection. As shown above, only one (0.8%) patient in the CT-based IMRT group developed asymptomatic temporal lobe radiation necrosis 23 months after radiation. This case developed in areas that received the prescription dose of 72.6 Gy because of intracranial tumor extension. The difference in brain toxicities between this study and that of Bakst et al. is likely because the CT-based IMRT group in the current report was treated to a lower fractionated dose. The PET/CT-guided DP-IMRT group presented here generally had smaller GTVnx-PET volumes for dose-escalation, which can explain the low incidence of brain toxicity observed in this work.

A number of studies have reported prognostic factors for NPC patients treated by chemoradiotherapy [1, 14, 28, 29]. EBV DNA is considered an important prognostic factor for NPC patients [28, 32, 33], and previous studies of stratified NPC patients have identified an EBV DNA concentration of 4000 copies/ml as a prognostic cut-off value [32, 33]. As shown above, EBV DNA level was a significant prognostic factor for LPFS, DFS, DMFS and OS. To the best of our knowledge, no previous study has explored the prognostic value of PET/CT-guided DP-IMRT in NPC patients. The current findings revealed dose painting (PET/CT-guided DP-IMRT vs CT-based IMRT without DP) to be a significant independent predictor for LFFS and DFS, with marginal significance in predicting DMFS and OS. However, the therapeutic benefits of PET/CT-guided DP-IMRT regimen should be explored in further prospective studies.

Limitations
This study was limited by its retrospective nature. Follow-up was not long enough for evaluating long term survival in NPC patients. The major treatment regimen was concurrent chemoradiotherapy with or without adjuvant chemotherapy; however, about a quarter of patients received induction chemotherapy, which may influence treatment homogeneity.

Conclusion
In summary, our findings indicated that PET/CT-guided DP-IMRT plus chemotherapy is an effective treatment modality for patients with locoregional advanced NPC. This study reiterates that addition of FDG-PET/CT-guided dose-painting to IMRT significantly improves survival with no increased toxicities compared with CT-based IMRT in locoregionally advanced NPC. Further prospective randomized studies should be conducted to better define the role of the PET/CT-guided DP-IMRT regimen in chemoradiation for locoregional advanced NPC.

Abbreviations
BED: Biologically effective dose; CR: Complete response; DFS: Disease free survival; DMFS: Distant metastasis-free survival; DNA: Deoxyribonucleic acid; DP: Dose painting; EBV: Epstein-Barr virus; FDG-PET/CT: 18F-fluorodeoxyglucose positron emission tomography/computed tomography; GTV: Gross tumor volume; GTVnd: GTV of the lymph node; GTVnx: GTV of nasopharynx; GTVnx-PET: Gross tumor volume of nasopharynx in PET images; IMRT: Intensity modulated radiation therapy; LFFS: Local failure-free survival; LPFS: Local progression-free survival; LRFFS: Ocoregional failure-free survival; NPC: Nasopharyngeal carcinoma; OS: Overall survival; RFFS: Regional failure-free survival; RT: Radiotherapy; RTOG: Radiation Therapy Oncology Group; SBR: Signal/background ratio; SIB: Simultaneous integrated boost; SUV: Standardized uptake value

Acknowledgements
Not applicable.

Funding
This study was supported by funding from Hunan Provincial Science and Technology Department (NO. 2016J1088), and from Health and Family Planning Commission of Hunan Province (No. B2016048).

Availability of data and materials
Materials in the manuscript are available by contacting the author at xixuping2010@126.com or wanghui710327@163.com.

Authors’ contributions
X-PX and HW led the design of the study, carried out target delineation, editing and submission of manuscript (X-PX and HW are the corresponding authors). FL, Y-QH, XF, YH, QH, LZ, QX, LL, YL, YM and H-ZM participated in target delineation, computation of treatment plans. FL involved in the design of the study, collection and analysis of data, and drafting of manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study obtained ethics approval from the Ethics Committee of Hunan Cancer Hospital.

Author details
1Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. 2Key Laboratory of Translational Radiation Oncology, Hunan Province Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

Received: 31 August 2016 Accepted: 6 December 2016
Published online: 13 January 2017

References
1. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patienstaphygeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163–71.
2. Tang LL, Chen WQ, Xue WQ, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer Lett. 2016;374(1):22–30.
3. Zong J, Lin S, Lin J, Tang L, et al. Impact of intensity-modulated radiotherapy on nasopharyngeal carcinoma: validation of the 7th edition AJCC staging system. Oral Oncol. 2015;51(3):254–9.
4. Liu F, Xiao JP, Xu GZ, et al. Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma. Radiat Oncol. 2013;8:157.
5. Qiu S, Lin S, Tham IW, et al. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2012;83:676–83.
6. Teo PM, Leung SF, Tung SY, et al. Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). Radiother Oncol. 2006;79(1):27–33.

7. Ren Y, Zhao Q, Liu H, et al. 3D-image-guided HDR-brachytherapy versus 2D HDR-brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma. BMC Cancer. 2014;14:894.

8. Rosenblatt E, Abdel-Wahab M, El-Gantiry M, et al. Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency. Radiother Oncol. 2014;119:77.

9. Wang JS, Zheng JN, Tang TY, et al. Survival benefit of induction chemotherapy in nasopharyngeal carcinoma: a phase III meta-analysis. Oral Oncol. 2011;47(3):262–8.

10. Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTDG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012;13(2):172–80.

11. Lee NY, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684–90.

12. Lin S, Pan J, Han L, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol. 2014;110(3):385–9.

13. Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103(23):1761–70.

14. Xu T, Liu Y, Dou S, et al. Weekly cetuximab concurrent with IMRT for nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency. Radiother Oncol. 2016;120(1):76–83.

15. Delouya G, Igidbashian L, Houle A, et al. 18F-FDG-PET imaging in nasopharyngeal carcinoma: a prospective randomized trial. J Nucl Med. 2012;53(9):1416–21.

16. He Y, Wang Y, Shen L, et al. Prognostic value of the distance between the primary tumor and brainstem in the patients with locally advanced nasopharyngeal carcinoma. BMC Cancer. 2016;16(1):114.

17. Song YQ, Wang WW, Tao GZ, et al. Survival benefit of induction chemotherapy in nasopharyngeal carcinoma: a time-to-event meta-analysis. Oral Oncol. 2015;51(8):873–9.

18. Liu LT, Tang LQ, Chen QY, et al. The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–9.

19. He Y, Wang Y, Shen L, et al. Prognostic value of the distance between the primary tumor and brainstem in the patients with locally advanced nasopharyngeal carcinoma. BMC Cancer. 2016;16(1):114.

20. Yu H, Caldwell C, Mah K, et al. Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images. Int J Radiat Oncol Biol Phys. 2011;80(1):148–53.

21. Rasmussen JH, Vogelius IR, Aznar MC, et al. Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. Acta Oncol. 2015;54(9):1416–21.

22. Liu LT, Tang LQ, Chen QY, et al. Prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–9.

23. He Y, Wang Y, Shen L, et al. Prognostic value of the distance between the primary tumor and brainstem in the patients with locally advanced nasopharyngeal carcinoma. BMC Cancer. 2016;16(1):114.

24. Yu H, Caldwell C, Mah K, et al. Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images. Int J Radiat Oncol Biol Phys. 2011;80(1):148–53.

25. Delouya G, Igidbashian L, Houle A, et al. 18F-FDG-PET imaging in nasopharyngeal carcinoma: a prospective randomized trial. J Nucl Med. 2012;53(9):1416–21.

26. He Y, Wang Y, Shen L, et al. Prognostic value of the distance between the primary tumor and brainstem in the patients with locally advanced nasopharyngeal carcinoma. BMC Cancer. 2016;16(1):114.

27. He Y, Wang Y, Shen L, et al. Prognostic value of the distance between the primary tumor and brainstem in the patients with locally advanced nasopharyngeal carcinoma. BMC Cancer. 2016;16(1):114.

28. Liu LT, Tang LQ, Chen QY, et al. The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–9.